Resecabtagene autoleucel

Cellares has successfully completed a Technology Adoption Program with Cabaletta Bio, demonstrating their Cell Shuttle platform can automate and scale manufacturing of rese-cel, a CAR-T therapy for autoimmune diseases including myositis, scleroderma, and lupus nephritis.

Clinical trials demonstrate significant efficacy of rese-cel across multiple autoimmune conditions, with three SLE patients achieving DORIS remission and successful discontinuation of immunosuppressants and steroids.

A phase Ib/II clinical trial led by Mount Sinai researchers demonstrates successful outcomes in combining chemotherapy with immunotherapy for diffuse large B-cell lymphoma treatment.

Cabaletta Bio has received FDA clearance to proceed with RESET-MS trial, testing their B-cell-targeting CAR T-cell therapy rese-cel in relapsing and progressive multiple sclerosis patients.

Cabaletta Bio will present updated clinical data on rese-cel at upcoming scientific meetings in February 2025, showcasing its potential in autoimmune diseases.